Erzurum City Hospital
Erzurum, Yakutiye, 25240, Turkey (Türkiye)
Location contact
Ahmet Ergün, MD
SUB_INVESTIGATOR
NCT Number: NCT07622641
This study is a prospective, randomized, controlled clinical trial designed to evaluate the optimal timing of midazolam administration in children undergoing adenotonsillectomy. The study will be conducted at the Departments of Otorhinolaryngology and Anesthesiology of Erzurum City Hospital.
Midazolam is commonly used in pediatric patients to reduce anxiety and improve perioperative comfort. However, the optimal timing of its administration (before surgery or during anesthesia induction) remains unclear. This study aims to compare the effects of preoperative oral midazolam and intraoperative intravenous midazolam on stress response, behavioral outcomes, and recovery quality.
Participants will be randomly assigned to one of two groups. In Group A, children will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery. In Group B, children will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.
The primary outcome of the study is the change in serum cortisol levels, which reflects the physiological stress response. Blood samples will be collected twice: once 10 minutes after anesthesia induction and once 15 minutes after surgery in the post-anesthesia care unit.
In addition to cortisol levels, the study will assess preoperative anxiety using an observational anxiety scale, postoperative pain using a behavioral pain scoring system, and parental satisfaction using a standardized questionnaire. These measures aim to provide a comprehensive evaluation of the child's perioperative experience.
The findings of this study may help determine the most effective timing of midazolam administration to reduce stress, improve recovery, and enhance overall patient and family satisfaction in pediatric surgical care.
Trial opening soon.
Get Notified3 year–10 year
All sexes
Interventional
Not applicable
Erzurum, Yakutiye, 25240, Turkey (Türkiye)
Ahmet Ergün, MD
SUB_INVESTIGATOR
This study is a prospective, randomized, controlled clinical trial designed to evaluate the effects of the timing of midazolam administration on physiological stress response, behavioral anxiety, postoperative pain, recovery quality, and parental satisfaction in pediatric patients undergoing elective adenotonsillectomy.
The primary objective is to compare the effect of midazolam administration timing on physiological stress response, assessed by serum cortisol levels. Secondary objectives include evaluating preoperative anxiety levels, postoperative pain scores, recovery quality, and parental satisfaction between groups receiving midazolam at different time points.
The study will include children aged 3-10 years, classified as ASA physical status I-II, scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy.
Eligible patients will be identified during preoperative anesthesia evaluation. Parents or legal guardians will be informed about the study, and written informed consent will be obtained prior to enrollment.
Participants will be randomly assigned to one of two groups using a computer-generated randomization sequence with sealed envelope allocation:
Group A (Preoperative Midazolam Group): Patients will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery, administered with a small volume of apple juice under clinical supervision.
Group B (Intraoperative Midazolam Group): Patients will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.
Anesthesia Protocol
To ensure comparability between groups, all patients will undergo a standardized anesthesia protocol. Vascular access will be established after inhalational induction using sevoflurane in oxygen, minimizing stress associated with intravenous cannulation.
Lidocaine (0.5-1 mg/kg) will be administered prior to propofol injection to reduce injection pain Propofol (2-3 mg/kg) will be used for induction Rocuronium (0.6 mg/kg) will be administered for neuromuscular blockade Fentanyl (1-2 µg/kg) will be used for analgesia
Anesthesia maintenance will be achieved with sevoflurane (2-3%) in a mixture of oxygen and air, targeting an age-adjusted MAC ≥1.3. Mechanical ventilation will be standardized with volume-controlled settings appropriate for age.
Intraoperative fluid management will be based on body weight using standard pediatric maintenance formulas and isotonic saline solution.
Neuromuscular blockade will be reversed with sugammadex (2 mg/kg) Extubation will be performed based on clinical recovery criteria, including adequate spontaneous respiration and responsiveness
All patients will receive intravenous paracetamol (10-15 mg/kg) for postoperative analgesia and ondansetron (0.1 mg/kg) for prophylaxis of nausea and vomiting.
Serum cortisol levels will be measured at two time points:
Intraoperative period (10 minutes after anesthesia induction) Early postoperative period (15 minutes after admission to the post-anesthesia care unit)
Cortisol levels will be analyzed using an electrochemiluminescence immunoassay method.
Preoperative anxiety will be assessed using a modified observational anxiety scale. Postoperative pain will be evaluated using a validated behavioral pain scoring system, and recovery status will be assessed using standard recovery criteria.
Parental satisfaction will be evaluated within the first 30 minutes after surgery using a structured questionnaire assessing overall perioperative experience.
All perioperative data will be recorded by the anesthesia team and post-anesthesia care unit staff. Collected data will be analyzed statistically to compare outcomes between the two groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral midazolam will be administered at a dose of 0.5 mg/kg, 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration.
Intravenous midazolam will be administered at a dose of 0.05-0.1 mg/kg during anesthesia induction.
Time frame: At 10 minutes after anesthesia induction and at 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Serum cortisol levels will be measured to assess physiological stress response.
Time frame: During the preoperative period before anesthesia induction
Preoperative anxiety will be assessed using the modified Yale Preoperative Anxiety Scale (mYPAS), an observational tool evaluating behavioral anxiety in children across multiple domains. Scores will be normalized to a 0-100 scale, with higher scores indicating greater anxiety.
Time frame: At 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Postoperative pain will be evaluated using the FLACC (Face, Legs, Activity, Cry, Consolability) scale, a validated behavioral pain assessment tool for pediatric patients. Each category is scored from 0 to 2, with a total score ranging from 0 to 10, where higher scores indicate more severe pain.
Time frame: Within the first 30 minutes postoperatively in the PACU
Recovery status will be assessed using the Modified Aldrete Score, which evaluates activity, respiration, circulation, consciousness, and oxygen saturation. Higher scores indicate better recovery and readiness for discharge from the PACU.
Time frame: Within 30 minutes after the child becomes clinically stable in the postoperative period
Parental satisfaction will be evaluated using the Pediatric Anesthesia Parent Satisfaction (PAPS) survey, a structured questionnaire assessing satisfaction with perioperative care, including communication, pain management, and overall experience. Scores range from 5 to 25, with higher scores indicating greater satisfaction.
Contact information is provided by the study sponsor or research team.
Ahmet Ergün, MD
CONTACT
Mehmet Sercan Orbak, MD
CONTACT
Erzurum City Hospital
Other
Optimization of Midazolam Administration Timing in Pediatric Adenotonsillectomy: Effects on Cortisol Response, Behavioral Stress, and Recovery Quality
Acronym: Timing-Midazol
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07558044
Adenotonsillectomy, Neurologic Manifestations
Caracas, Miranda, Venezuela
View Trial DetailsNCT07479602
Adenotonsillectomy, Children
Beijing, Beijing Municipality, China
View Trial DetailsNCT01096797
Adenotonsillectomy, Confusion
Monza, MB, Italy
View Trial DetailsNCT00849966
Adenotonsillectomy, Chemically-Induced Disorders
Ottawa, Ontario, Canada
View Trial Details